383 related articles for article (PubMed ID: 17906635)
21. Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.
Shimamura K; Nagumo A; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
Eur J Pharmacol; 2010 Mar; 630(1-3):34-41. PubMed ID: 20045404
[TBL] [Abstract][Full Text] [Related]
22. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet.
Shih CC; Lin CH; Lin WL
Diabetes Res Clin Pract; 2008 Aug; 81(2):134-43. PubMed ID: 18550200
[TBL] [Abstract][Full Text] [Related]
23. Elovl6 promotes nonalcoholic steatohepatitis.
Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H
Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171
[TBL] [Abstract][Full Text] [Related]
24. CXCL14 and insulin action.
Hara T; Nakayama Y
Vitam Horm; 2009; 80():107-23. PubMed ID: 19251036
[TBL] [Abstract][Full Text] [Related]
25. In vivo leptin infusion impairs insulin and leptin signalling in liver and hypothalamus.
Benomar Y; Wetzler S; Larue-Achagiotis C; Djiane J; Tomé D; Taouis M
Mol Cell Endocrinol; 2005 Oct; 242(1-2):59-66. PubMed ID: 16150536
[TBL] [Abstract][Full Text] [Related]
26. The effect of LXRα, ChREBP and Elovl6 in liver and white adipose tissue on medium- and long-chain fatty acid diet-induced insulin resistance.
Sun H; Jiang T; Wang S; He B; Zhang Y; Piao D; Yu C; Wu N; Han P
Diabetes Res Clin Pract; 2013 Dec; 102(3):183-92. PubMed ID: 24262945
[TBL] [Abstract][Full Text] [Related]
27. Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance.
Moon YA; Ochoa CR; Mitsche MA; Hammer RE; Horton JD
J Lipid Res; 2014 Dec; 55(12):2597-605. PubMed ID: 25281760
[TBL] [Abstract][Full Text] [Related]
28. Leptin resistance following over-expression of protein tyrosine phosphatase 1B in liver.
Lam NT; Covey SD; Lewis JT; Oosman S; Webber T; Hsu EC; Cheung AT; Kieffer TJ
J Mol Endocrinol; 2006 Feb; 36(1):163-74. PubMed ID: 16461936
[TBL] [Abstract][Full Text] [Related]
29. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein.
Miyamoto H; Moriishi K; Moriya K; Murata S; Tanaka K; Suzuki T; Miyamura T; Koike K; Matsuura Y
J Virol; 2007 Feb; 81(4):1727-35. PubMed ID: 17135326
[TBL] [Abstract][Full Text] [Related]
30. Insulin signaling in health and disease.
White MF
Science; 2003 Dec; 302(5651):1710-1. PubMed ID: 14657487
[TBL] [Abstract][Full Text] [Related]
31. GADD34-deficient mice develop obesity, nonalcoholic fatty liver disease, hepatic carcinoma and insulin resistance.
Nishio N; Isobe K
Sci Rep; 2015 Aug; 5():13519. PubMed ID: 26316333
[TBL] [Abstract][Full Text] [Related]
32. Ablation of Elovl6 protects pancreatic islets from high-fat diet-induced impairment of insulin secretion.
Tang N; Matsuzaka T; Suzuki M; Nakano Y; Zao H; Yokoo T; Suzuki-Kemuriyama N; Kuba M; Okajima Y; Takeuchi Y; Kobayashi K; Iwasaki H; Yatoh S; Takahashi A; Suzuki H; Sone H; Shimada M; Nakagawa Y; Yahagi N; Yamada N; Shimano H
Biochem Biophys Res Commun; 2014 Jul; 450(1):318-23. PubMed ID: 24938128
[TBL] [Abstract][Full Text] [Related]
33. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice.
Matsuzaka T; Kuba M; Koyasu S; Yamamoto Y; Motomura K; Arulmozhiraja S; Ohno H; Sharma R; Shimura T; Okajima Y; Han SI; Aita Y; Mizunoe Y; Osaki Y; Iwasaki H; Yatoh S; Suzuki H; Sone H; Takeuchi Y; Yahagi N; Miyamoto T; Sekiya M; Nakagawa Y; Ema M; Takahashi S; Tokiwa H; Shimano H
Hepatology; 2020 May; 71(5):1609-1625. PubMed ID: 31529722
[TBL] [Abstract][Full Text] [Related]
34. Role of caveolins in body weight and insulin resistance regulation.
Frühbeck G; López M; Diéguez C
Trends Endocrinol Metab; 2007 Jul; 18(5):177-82. PubMed ID: 17433707
[TBL] [Abstract][Full Text] [Related]
35. Glycosphingolipids and insulin resistance.
Langeveld M; Aerts JM
Prog Lipid Res; 2009; 48(3-4):196-205. PubMed ID: 19303901
[TBL] [Abstract][Full Text] [Related]
36. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance.
Tsukumo DM; Carvalho-Filho MA; Carvalheira JB; Prada PO; Hirabara SM; Schenka AA; Araújo EP; Vassallo J; Curi R; Velloso LA; Saad MJ
Diabetes; 2007 Aug; 56(8):1986-98. PubMed ID: 17519423
[TBL] [Abstract][Full Text] [Related]
37. Enhanced insulin sensitivity in mice lacking ganglioside GM3.
Yamashita T; Hashiramoto A; Haluzik M; Mizukami H; Beck S; Norton A; Kono M; Tsuji S; Daniotti JL; Werth N; Sandhoff R; Sandhoff K; Proia RL
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3445-9. PubMed ID: 12629211
[TBL] [Abstract][Full Text] [Related]
38. [Role of Fatty Acid Elongase Elovl6 in the Regulation of Fatty Acid Quality and Lifestyle-related Diseases].
Matsuzaka T; Shimano H
Yakugaku Zasshi; 2022; 142(5):473-476. PubMed ID: 35491151
[TBL] [Abstract][Full Text] [Related]
39. Obesity, insulin resistance and hepatic perfusion.
Brock RW; Dorman RB
Microcirculation; 2007; 14(4-5):339-47. PubMed ID: 17613806
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.
Holland WL; Brozinick JT; Wang LP; Hawkins ED; Sargent KM; Liu Y; Narra K; Hoehn KL; Knotts TA; Siesky A; Nelson DH; Karathanasis SK; Fontenot GK; Birnbaum MJ; Summers SA
Cell Metab; 2007 Mar; 5(3):167-79. PubMed ID: 17339025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
